Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chi-GVM for Relapsed/Refractory Peripheral T-cell Lymphoma
NCT06211881Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Oct 2023; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06211881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211881.